The Special Drug Use-results Survey (All-Case Surveillance) of Ofev Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan

Trial Profile

The Special Drug Use-results Survey (All-Case Surveillance) of Ofev Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Aug 2017 Planned End Date changed from 30 Aug 2018 to 31 Jan 2020.
    • 22 Aug 2017 Planned primary completion date changed from 30 Aug 2018 to 31 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top